Navigation Links
Genzyme Reports Strong First-Quarter Growth
Date:4/23/2008

p> patients. Preliminary data from this trial will be presented at the

American Society of Clinical Oncology meeting in June.

Genzyme is developing a new filing for the adult AML indication in

Europe. This follows its withdrawal of Bioenvision's marketing

application, which, as expected, an advisory committee deemed

insufficient to support approval. Genzyme expects to make a new

submission as early as the fourth quarter of this year that will

include a more robust data package from Genzyme sponsored studies.

Alemtuzumab for multiple sclerosis

-- Final, three-year efficacy and safety data from the Phase 2 trial

comparing alemtuzumab with Rebif (interferon beta-1a) for the treatment

of relapsing-remitting multiple sclerosis were presented last week

during a scientific platform session at the American Academy of

Neurology meeting by Dr. Alasdair Coles. These results confirm all

trends observed in the one- and two-year interim analyses. The two

ongoing Phase 3 trials further examining the efficacy and safety of

alemtuzumab for the treatment of MS are progressing. These two studies

are currently enrolling patients at sites in the United States, Europe,

Latin America and Australia. Genzyme believes that alemtuzumab has the

potential to be the best therapy in a market for MS drugs that is

projected to reach $8-9 billion annually when the treatment is expected

to be ready for launch in 2011-2012. Alemtuzumab is being developed in

collaboration with Bayer Schering Pharma AG, Germany.

Genz-112638 for Gaucher disease

-- Genzyme is making excellent progress in developing the small molecule

Genz-112638, a novel oral therapy intended for the treatment of Gaucher

disease. Initial results released one year ago for the first group of

stud
'/>"/>

SOURCE Genzyme Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related biology technology :

1. Genzyme to Build New R&D Center in Beijing
2. Genzyme Provides Update on Myozyme(R) Manufacturing
3. Genzyme Withdraws Bioenvisions European Filing of Evoltra(R) in Elderly AML Patients
4. Genzyme Launches Renvela(R) in the U.S. for Dialysis Patients
5. Genzyme and Isis Announce Hart-Scott-Rodino Approval of Collaboration
6. Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen
7. BioMarin and Genzyme Restructure Aldurazyme 50/50 Joint Venture
8. Genzyme Receives European CE Mark for Single-Treatment Synvisc-One(TM)
9. Genzyme Announces FDA Approval of Thyrogen(R) for Use in Thyroid Cancer Ablation
10. Genzyme Study of Myozyme(R) for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints
11. Genzyme and Sunway to Collaborate on Gene Therapy Program in China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)...  Roka Bioscience, Inc. (NASDAQ: ROKA ), a ... the detection of foodborne pathogens, today announced that Paul ... th Annual Healthcare Conference on December 2, 2014 at ... York Palace in New York, NY . ... Company, its operations, strategies and prospects may be discussed. To ...
(Date:11/24/2014)... Belgium , Nov. 24, 2014 ... focused on developing diagnostic tests for cancer and other conditions, ... will be presented at the Science for Business BioWin Day ... Belgium . The data come from VolitionRx,s lung cancer ... Pneumology department of the Centre Hospitalier Universitaire (CHU) de Liege ...
(Date:11/24/2014)... (PRWEB) November 24, 2014 Continental ... patient populations into clinical trials at its mid-Atlantic ... , “Continental was created with the idea of ... a fundamental role in medical advances," said Continental's ... syphilis experiment to the immortal cell line of ...
(Date:11/24/2014)... 2014 Senior Vice President, General ... leadership skills, business acumen Elsevier , ... products and services, congratulates Diane Bartoli , Senior ... Workflow, Elsevier Clinical Solutions, for being recognized in the ... Awards issue of Profiles in Diversity Journal ...
Breaking Biology Technology:Roka Bioscience to Present at the Piper Jaffray Healthcare Conference 2VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 2VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 3VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 4VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 5VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 6At Continental Clinical Solutions, CEO Saleh Stevens Focuses on Diversity in Clinical Trial Recruitment at Maryland Site 2At Continental Clinical Solutions, CEO Saleh Stevens Focuses on Diversity in Clinical Trial Recruitment at Maryland Site 3Elsevier Clinical Solutions' Diane Bartoli Featured In Profiles in Diversity Journal's 13th Annual Women Worth Watching Issue 2Elsevier Clinical Solutions' Diane Bartoli Featured In Profiles in Diversity Journal's 13th Annual Women Worth Watching Issue 3
... and Families, EMERYVILLE, Calif., April 15 ... two new health care areas designed to,soothe patients ... to offer health resources. The Carol Ann,Read Breast ... procedures, all in one location, for the quickest ...
... Able to Detect a Single Cancer Cell Through In Vivo ... ... Caliper Life,Sciences, Inc. (Nasdaq: CALP ) today introduced Bioware(R) Ultra cell ... in vivo imaging applications. Bioware Ultra cell lines are,10 to 100 times ...
... Pittsburgh-based Foundation,Radiology Group (FRG), a full-service ... diagnostic images for hospitals,announced today that James ... the,position of Chief Medical Officer. The appointment ... nationwide network of radiology physician groups to,provide ...
Cached Biology Technology:Alta Bates Summit Medical Center Opens Two Warm, Supportive Patient Centers: Carol Ann Read Breast Health Center and Family Resource Center 2Alta Bates Summit Medical Center Opens Two Warm, Supportive Patient Centers: Carol Ann Read Breast Health Center and Family Resource Center 3Increased Light Leads to Early Detection: Caliper Life Sciences Introduces Bioware(R) Ultra Cancer Cell Lines 2Increased Light Leads to Early Detection: Caliper Life Sciences Introduces Bioware(R) Ultra Cancer Cell Lines 3James W. Backstrom, M.D., Named Chief Medical Officer of Foundation Radiology Group 2James W. Backstrom, M.D., Named Chief Medical Officer of Foundation Radiology Group 3
(Date:11/4/2014)... of Medicine announced today that it is a ... the Bill & Melinda Gates Foundation. Laura ... Reproductive Sciences; and Vice Chair of Research and ... will pursue an innovative global health and development ... Fetal Neurodevelopment.", Grand Challenges Explorations (GCE) funds individuals ...
(Date:11/4/2014)... VILNIUS, Lithuania , Nov. 4, 2014 /PRNewswire/ ... identification technologies, today announced that the latest version ... place in the Ongoing MINEX evaluation ... interoperability of fingerprint algorithms using the INCITS 378 ... a mandatory requirement in public tenders in ...
(Date:11/2/2014)... month,s issue of Physics World , James Dacey ... "valley of death" to take their innovations from the ... the gruelling challenge facing all start-up companies as they ... physicists because of two main factors: physics-based inventions are ... often turn out to be a lot more complicated ...
Breaking Biology News(10 mins):Temple University School of Medicine receives Grand Challenges Explorations grant 2Neurotechnology Places Second in Ongoing MINEX Ranking for Fingerprint Matching Algorithms 2Neurotechnology Places Second in Ongoing MINEX Ranking for Fingerprint Matching Algorithms 3The 'valley of death' facing physics start-ups 2
... that some biological structures, like the brain or the ... explain. Biologists have proposed various ways that so-called ,irreducibly ... bit. But a new study proposes an alternative route. ... becoming more intricate, say authors Dan McShea and Wim ...
... Ohio American adults who prepare their own meals and ... on one of those activities at the expense of the ... a 10-minute increase in food preparation time was associated with ... for both men and women. The finding applied to single ...
... helpers (nannies) in a cichlid fish allow the dominant male ... and territory, according to new research published today in ... 30 days which corresponds to one breeding cycle in ... and the University of Bern (Switzerland) studied the investment strategies ...
Cached Biology News:Study proposes alternative way to explain life's complexity 2Study proposes alternative way to explain life's complexity 3Exercise or make dinner? Study finds adults trade one healthy act for another 2Exercise or make dinner? Study finds adults trade one healthy act for another 3
IHC detection kit for PCNA in cells and tissues...
... Immunogen: Synthetic peptide derived from the ... protein. Specificity: Reacts with the ... Reactivity: Human Mouse (positive controls: WNT1-transfected ... lysates and mouse Mouse-1 cell lysates). ...
The pYES2 vector is designed for native expression of your protein of interest in S. cerevisiae. It contains the URA3 gene for selection in yeast and 2 origin for high-copy maintenance....
... cAMP - [125I] Direct SPA ... SPA.Includes lysis reagents that eliminate lengthy ... cAMP measurement (optional use).Range: 1.32-84.28 ng/ml ... pmol/ml).Overnight protocol.Store at 2-8 C. Category: ...
Biology Products: